Pronounced local skin reaction to ingenol mebutate against actinic keratosis in kidney transplant recipient without systemic adverse events

Mohanna, M. T.; Hofbauer, Günther F.L.

doi:10.1016/j.jdcr.2015.09.011

Cited by 8 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A case report showed full clinical remission of multiple AKs with good aesthetic outcome in a patient with organ transplant, which used IM on large skin areas. This suggests that IM may be used on large areas, even on 100 cm 2 of skin, resembling field cancerization treatment by photodynamic therapy without the systemic side effects [121]. There is also evidence that IM treats subclinical lesions present in photodamaged skin and reduces the number of tumors that develop in UV-exposed skin [106].…”

Section: Introductionmentioning

confidence: 99%

Mediators of Inflammation in Topical Therapy of Skin Cancers

Voiculescu

Lisievici

Lupu

et al. 2019

Mediators of Inflammation

View full text Add to dashboard Cite

Taking into consideration that the immune system plays a very important role in the development of melanoma and non-melanoma skin cancers, which have a high prevalence in immunosuppressed patients and after prolonged ultraviolet radiation, the interest in developing novel therapies, in particular targeting the inflammation in cancer, has increased in the past years. The latest data suggest that therapies such as imiquimod (IMQ), ingenol mebutate (IM), 5-fluorouracil (5-FU), retinoids, and nonsteroidal anti-inflammatory drugs (NSAIDs) have been used with success in the topical treatment of some cancers. Herein, we review the topical treatment targeting the inflammation in skin cancer and the mechanisms involved in these processes. Currently, various associations have shown a superior success rate than monotherapy, such as systemic acitretin and topical IMQ, topical 5-FU with tretinoin cream, or IMQ with checkpoint inhibitor cytotoxic T lymphocyte antigen 4. Novel therapies targeting Toll-like receptor-7 (TLR-7) with higher selectivity than IMQ are also of great interest.

show abstract

Section: Introductionmentioning

confidence: 99%

Mediators of Inflammation in Topical Therapy of Skin Cancers

Voiculescu

Lisievici

Lupu

et al. 2019

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…D ear E ditor , Immunosuppressed solid organ transplant recipients (SOTRs) have a high burden of actinic keratosis (AK), but they have been excluded from clinical trials of ingenol mebutate 0·015% gel. This leaves dermatologists and transplant teams to extrapolate safety data from immunocompetent patients or from two case reports of its use in SOTRs . This single‐arm, open‐label, investigator‐initiated study investigated the safety and tolerability of topical ingenol mebutate 0·015% gel in SOTRs.…”

mentioning

confidence: 99%

Ingenol mebutate 0·015% gel is safe for short‐term treatment of actinic keratoses on the face in solid organ transplant recipients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Most topical pharmacotherapies induce inflammation with long application period ranging from weeks to months. IM is an active compound in the sap of Euphorbia peplus and has 2 mechanisms of action, including necrosis within hours and cellular cytotoxicity within days, making it a very rapid topical treatment modality [1,5] . IM has been registered in the United States, the European Union and in Switzerland as a treatment for AK since 2012 [5] .…”

mentioning

confidence: 99%

“…IM is an active compound in the sap of Euphorbia peplus and has 2 mechanisms of action, including necrosis within hours and cellular cytotoxicity within days, making it a very rapid topical treatment modality [1,5] . IM has been registered in the United States, the European Union and in Switzerland as a treatment for AK since 2012 [5] . One advantage of using IM is the short treating course, which could improve patient compliance [1,4,5] .…”

mentioning

confidence: 99%

“…IM has been registered in the United States, the European Union and in Switzerland as a treatment for AK since 2012 [5] . One advantage of using IM is the short treating course, which could improve patient compliance [1,4,5] . A clinical study with Euphorbia peplus sap with an active ingredient IM (PEP005) showed that the effectiveness of IM is not limited to superficial AK only but also extends to clinical healing of IEC in 94% of patients studied [1] .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Bowenoid Actinic Keratosis and Bowen's Disease Treated Successfully with Ingenol Mebutate

Mohanna

Hofbauer²

2016

Dermatology

View full text Add to dashboard Cite

Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis (AK). We report 2 cases with off-label use of IM. The first case of bowenoid AK was treated with 150 μg IM for 3 consecutive days with an almost complete clinical remission of the lesion. The second case of Bowen's disease was treated with 500 μg IM for 2 consecutive days leading to complete clinical remission.

show abstract

Pronounced local skin reaction to ingenol mebutate against actinic keratosis in kidney transplant recipient without systemic adverse events

Cited by 8 publications

References 6 publications

Mediators of Inflammation in Topical Therapy of Skin Cancers

Mediators of Inflammation in Topical Therapy of Skin Cancers

Ingenol mebutate 0·015% gel is safe for short‐term treatment of actinic keratoses on the face in solid organ transplant recipients

Bowenoid Actinic Keratosis and Bowen's Disease Treated Successfully with Ingenol Mebutate

Contact Info

Product

Resources

About